Poolbeg Pharma a year of substantial progress

Poolbeg Pharma
[shareaholic app="share_buttons" id_name="post_below_content"]

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting 2022 have been posted to shareholders.

The Notice of AGM and accompanying form of proxy are available to download from the Company’s website: https://www.poolbegpharma.com/investors/documents/  while the 2022 Annual Report and Accounts can be viewed and downloaded below.

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 11 May 2023 at 12pm.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
Poolbeg Pharma to showcase POLB 001's promising results in reducing CRS at ASH 2024, highlighting breakthroughs in cancer immunotherapy safety.
Discover six high-growth AIM-listed British companies delivering exceptional returns, with share prices surging up to 150% in the past year.

Search

Search